Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Laboratorios Farmaceuticos Rovi, S.A.

Market Cap 2.97B 3.44B 2.74B 2.56B 4.8B 327B 4.87B 32.31B 12.6B 159B 12.9B 12.63B 551B P/E Ratio 2026 *
22.2x
P/E Ratio 2027 * 16.3x
Enterprise Value 2.95B 3.41B 2.72B 2.54B 4.76B 324B 4.84B 32.06B 12.5B 158B 12.8B 12.53B 547B EV / Sales 2026 *
3.81x
EV / Sales 2027 * 3.15x
Free-Float
31.63%
Yield 2026 *
1.68%
Yield 2027 * 2.02%
3 years 50.88
Extreme 50.88
90.61
5 years 0.03
Extreme 0.03
90.61
10 years 0.03
Extreme 0.03
90.61
Manager TitleAgeSince
Chief Executive Officer - 27/07/2007
Director of Finance/CFO - 01/01/2001
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman - 17/07/2021
Director/Board Member - 27/07/2007
Director/Board Member - 27/07/2007
Change 5-day change 1-year change 3-year change Capi.($)
-27.31%-.--% - - 3.42B
-1.48%+1.07%+40.82%+156.79% 1,035B
+0.48%+2.90%+52.89%+49.79% 574B
+0.96%-0.22%+17.83%+64.62% 397B
+0.58%+0.77%+21.19%+15.95% 324B
-0.85%-2.86%+22.05%+13.80% 281B
+0.44%+3.48%+24.48%+34.39% 278B
+1.66%+5.61%-44.67%-47.49% 193B
+0.17%+1.45%+19.29%+63.16% 191B
-0.37%-3.34%+11.42%+60.35% 156B
Average -2.55%+1.68%+18.37%+45.71% 381.1B
Weighted average by Cap. -0.14%+2.39%+28.11%+72.15%

Financials

2026 *2027 *
Net sales 774M 896M 713M 668M 1.25B 85.18B 1.27B 8.42B 3.28B 41.46B 3.36B 3.29B 144B 913M 1.06B 841M 788M 1.48B 100B 1.5B 9.94B 3.87B 48.91B 3.97B 3.88B 169B
Net income 133M 154M 123M 115M 215M 14.63B 218M 1.45B 564M 7.12B 578M 566M 24.66B 183M 211M 168M 157M 295M 20.09B 300M 1.99B 775M 9.78B 793M 776M 33.86B
Net Debt -22.53M -26.09M -20.76M -19.44M -36.42M -2.48B -36.99M -245M -95.59M -1.21B -97.91M -95.83M -4.18B -90.52M -105M -83.42M -78.08M -146M -9.96B -149M -985M -384M -4.85B -393M -385M -16.79B
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
1,998
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
58.05EUR
Average target price
75.38EUR
Spread / Average Target
+29.85%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!